Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02476409 · ClinicalTrials.gov registry record · Phase 4
Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT02476409 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 40 participants.
The verdict
NCT02476409, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
Patients who present to clinic or in the outpatient setting with worsening heart failure represent a unique opportunity for novel approaches to decongestion (removing fluid) that may more rapidly improve fluid status and symptoms as well as reduce the risk of hospitalization. In these patients with less severe congestion (fluid overload), combining the vasopressin antagonist tolvaptan with loop diuretics (or fluid pills like furosemide/bumetanide/torsemide) may represent a more effective strategy for decongestion. In addition, looking at patients' copeptin levels may help identify those who are more likely to respond to tolvaptan.
Interventions
- OTHER Placebo
- DRUG tolvaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-07 |
| Est. Completion | 2021-05-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02476409
The ClinicalTrials.gov registry entry for NCT02476409 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02476409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02476409 about?
NCT02476409 is a clinical study titled "Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders". Patients who present to clinic or in the outpatient setting with worsening heart failure represent a unique opportunity for novel approaches to decongestion (removing fluid) that may more rapidly improve fluid status and symptoms as well as reduce the risk of hospitalization. In these patients with...
What is the current status of trial NCT02476409?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2015-07. Estimated completion is 2021-05-13.
What interventions are being tested in trial NCT02476409?
The interventions under investigation include: Placebo (OTHER), tolvaptan (DRUG).
Who is sponsoring clinical trial NCT02476409?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.